Hepatologia

Toward functional cure of hepatitis B: Is combination therapy the key?

Journal of hepatology. 2025 Jul; 83(Jul):271-272. doi: 10.1016/j.jhep.2025.03.024. pii: S0168-8278(25)00212-0.

Extracellular Vesicles and Micro-RNAs in Liver Disease.

Seminars in liver disease. 2025 Jun; 45(Jun):167-179. doi: 10.1055/a-2494-2233. pii: .

Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach.

Circulation. 2025 Jan; 151(Jan):98-119. doi: 10.1161/CIRCULATIONAHA.124.070535. pii: .

Impact of cardiometabolic risk factors for metabolic dysfunction-associated steatotic liver disease on mortality.

Nutrition, metabolism, and cardiovascular diseases : NMCD. 2025 Jun; 35(Jun):103965. doi: 10.1016/j.numecd.2025.103965. pii: S0939-4753(25)00119-X.

Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults.

Scientific reports. 2025 Feb; 15(Feb):5777. doi: 10.1038/s41598-025-89293-6. pii: 5777.

The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment.

Journal of clinical medicine. 2025 Jan; 14(Jan):doi: 10.3390/jcm14020428. pii: 428.

Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease.

Current cardiology reports. 2025 Jan; 27(Jan):19. doi: 10.1007/s11886-024-02181-9. pii: .

Metabolic dysfunction-associated steatotic liver disease in adults.

Nature reviews. Disease primers. 2025 Mar; 11(Mar):14. doi: 10.1038/s41572-025-00599-1. pii: .

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.

Journal of hepatology. 2025 Feb; 82(Feb):315-374. doi: 10.1016/j.jhep.2024.08.028. pii: S0168-8278(24)02508-X.

Hepatitis E virus infection in immunosuppressed patients and its clinical manifestations.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2025 Feb; 57(Feb):378-384. doi: 10.1016/j.dld.2024.06.020. pii: S1590-8658(24)00830-2.

Embolic and Ablative Therapy for Hepatocellular Carcinoma.

Clinics in liver disease. 2025 Feb; 29(Feb):87-103. doi: 10.1016/j.cld.2024.08.003. pii: S1089-3261(24)00071-0.

Management of Chronic Liver Disease in Patients with Hepatocellular Carcinoma.

Clinics in liver disease. 2025 Feb; 29(Feb):135-147. doi: 10.1016/j.cld.2024.08.004. pii: S1089-3261(24)00072-2.

Dumping syndrome: Update on pathophysiology, diagnosis, and management.

Neurogastroenterology and motility. 2025 Feb; 37(Feb):e14962. doi: 10.1111/nmo.14962. pii: .

Drug approvals in gastroenterology and hepatology in 2024.

Nature reviews. Gastroenterology & hepatology. 2025 Feb; 22(Feb):83. doi: 10.1038/s41575-025-01036-0. pii: .

The Diagnosis and Staging of Hepatocellular Carcinoma: A Review of Current Practices.

Clinics in liver disease. 2025 Feb; 29(Feb):33-48. doi: 10.1016/j.cld.2024.08.007. pii: S1089-3261(24)00086-2.

Hemochromatosis.

Annals of internal medicine. 2025 Feb; 178(Feb):ITC17-ITC32. doi: 10.7326/ANNALS-24-03710. pii: .

Immune Dysfunction and Infection Risk in Advanced Liver Disease.

Gastroenterology. 2025 Feb; doi: 10.1053/j.gastro.2024.08.046. pii: S0016-5085(24)05694-4.

Novel Emerging Mechanisms in Acetaminophen (APAP) Hepatotoxicity.

Liver international : official journal of the International Association for the Study of the Liver. 2024 Nov; doi: 10.1111/liv.16167. pii: .

Hyperammonaemia: review of the pathophysiology, aetiology and investigation.

Pathology. 2024 Oct; 56(Oct):763-772. doi: 10.1016/j.pathol.2024.06.002. pii: S0031-3025(24)00177-6.

Hepatitis E virus: from innate sensing to adaptive immune responses.

Nature reviews. Gastroenterology & hepatology. 2024 Oct; 21(Oct):710-725. doi: 10.1038/s41575-024-00950-z. pii: .

The Story of Ammonia in Liver Disease: An Unraveling Continuum.

Journal of clinical and experimental hepatology. 2024 ; 14():101361. doi: 10.1016/j.jceh.2024.101361. pii: 101361.

Mesenchymal Neoplasms of the Liver.

Surgical pathology clinics. 2023 Sep; 16(Sep):609-634. doi: 10.1016/j.path.2023.04.013. pii: S1875-9181(23)00039-9.

How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting.

Seminars in liver disease. 2023 May; 43(May):142-148. doi: 10.1055/s-0043-1770984. pii: .

Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Aug; 40(Aug):2763-2773. doi: 10.1200/JCO.21.02605. pii: .

Hepatocellular carcinoma.

Lancet (London, England). 2022 10; 400(10):1345-1362. doi: 10.1016/S0140-6736(22)01200-4. pii: S0140-6736(22)01200-4.

A multi-society Delphi consensus statement on new fatty liver disease nomenclature.

Journal of hepatology. 2023 Jun; doi: 10.1016/j.jhep.2023.06.003. pii: S0168-8278(23)00418-X.

EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.

Journal of hepatology. 2023 Jul; 79(Jul):181-208. doi: 10.1016/j.jhep.2023.03.010. pii: S0168-8278(23)00185-X.

EASL Clinical Practice Guidelines on hepatitis delta virus.

Journal of hepatology. 2023 Aug; 79(Aug):433-460. doi: 10.1016/j.jhep.2023.05.001. pii: S0168-8278(23)00317-3.

EASL Clinical Practice Guidelines on acute-on-chronic liver failure.

Journal of hepatology. 2023 Aug; 79(Aug):461-491. doi: 10.1016/j.jhep.2023.04.021. pii: S0168-8278(23)00244-1.

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.

Journal of hepatology. 2023 Nov; 79(Nov):1254-1269. doi: 10.1016/j.jhep.2023.06.002. pii: S0168-8278(23)00417-8.

ACG Clinical Guideline: Focal Liver Lesions.

The American journal of gastroenterology. 2024 Jul; 119(Jul):1235-1271. doi: 10.14309/ajg.0000000000002857. pii: .

Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy.

Drug safety. 2024 Apr; 47(Apr):321-332. doi: 10.1007/s40264-024-01399-4. pii: .

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

Hepatology (Baltimore, Md.). 2023 Dec; 78(Dec):1922-1965. doi: 10.1097/HEP.0000000000000466. pii: .

AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.

Gastroenterology. 2024 Jan; 166(Jan):202-210. doi: 10.1053/j.gastro.2023.10.016. pii: S0016-5085(23)05143-0.

AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.

Gastroenterology. 2023 Oct; 165(Oct):1080-1088. doi: 10.1053/j.gastro.2023.06.013. pii: S0016-5085(23)00881-8.

Toward functional cure of hepatitis B: Is combination therapy the key?

Journal of hepatology. 2025 Jul; 83(Jul):271-272. doi: 10.1016/j.jhep.2025.03.024. pii: S0168-8278(25)00212-0.

Reassessing the Prevalence of Portopulmonary Hypertension: Insights From a Prospective Study in Cirrhotic Patients.

Mayo Clinic proceedings. 2025 Jun; 100(Jun):1077-1080. doi: 10.1016/j.mayocp.2025.03.019. pii: S0025-6196(25)00173-9.

Extracellular Vesicles and Micro-RNAs in Liver Disease.

Seminars in liver disease. 2025 Jun; 45(Jun):167-179. doi: 10.1055/a-2494-2233. pii: .

Impact of cardiometabolic risk factors for metabolic dysfunction-associated steatotic liver disease on mortality.

Nutrition, metabolism, and cardiovascular diseases : NMCD. 2025 Jun; 35(Jun):103965. doi: 10.1016/j.numecd.2025.103965. pii: S0939-4753(25)00119-X.

Mayo Clinic Proceedings and Steatohepatitis: From NASH Recognition to MASH Therapy.

Mayo Clinic proceedings. 2025 May; doi: 10.1016/j.mayocp.2025.03.030. pii: S0025-6196(25)00185-5.

Metabolic dysfunction-associated steatotic liver disease and the cardiovascular system.

Trends in cardiovascular medicine. 2025 May; 35(May):258-265. doi: 10.1016/j.tcm.2025.01.001. pii: S1050-1738(25)00006-4.

Gastroenterology/Hepatology: What You May Have Missed in 2024.

Annals of internal medicine. 2025 May; 178(May):S39-S53. doi: 10.7326/ANNALS-25-00959. pii: .

Metabolic Dysfunction-Associated Steatotic Liver Disease as a Cardiovascular Risk Factor: Focus on Atrial Fibrillation.

Cardiology in review. 2025 Apr; doi: 10.1097/CRD.0000000000000932. pii: .

Case 9-2025: A 59-Year-Old Man with Hepatocellular Carcinoma.

The New England journal of medicine. 2025 Mar; 392(Mar):1216-1227. doi: 10.1056/NEJMcpc1909622. pii: .

Metabolic dysfunction-associated steatotic liver disease in adults.

Nature reviews. Disease primers. 2025 Mar; 11(Mar):14. doi: 10.1038/s41572-025-00599-1. pii: .